Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

Impacto

Downloads

Downloads per month over past year

Schettini, Francesco and Giuliano, Mario and Lambertini, Matteo and Bartsch, Rupert and Pinato, David James and Onesti, Concetta Elisa and Harbeck, Nadia and Lüftner, Diana and Rottey, Sylvie and van Dam, Peter A. and Zaman, Khalil and Mustacchi, Giorgio and Gligorov, Joseph and Awada, Ahmad and Campone, Mario and Wildiers, Hans and Gennari, Alessandra and Tjan-Heijnen, Vivianne C. G. and Cortes, Javier and Locci, Mariavittoria and Paris, Ida and Del Mastro, Lucia and De Placido, Sabino and Martín Jiménez, Miguel José and Jerusalem, Guy and Venturini, Sergio and Curigliano, Giuseppe and Generali, Daniele (2021) Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 13 (17). p. 4421. ISSN 2072-6694

[thumbnail of cancers-13-04421-v2.pdf]
Preview
PDF
Creative Commons Attribution.

1MB

Official URL: https://doi.org/10.3390/cancers13174421




Abstract

Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.


Item Type:Article
Uncontrolled Keywords:anthracyclines; breast cancer; triple negative; hormone receptor; metastatic; non-pegylated liposomal doxorubicin
Subjects:Medical sciences > Medicine > Endocrinology
Medical sciences > Medicine > Oncology
ID Code:70888
Deposited On:02 Mar 2022 14:23
Last Modified:03 Mar 2022 09:06

Origin of downloads

Repository Staff Only: item control page